ETFs & Funds
recent chart action. Price appreciation+Volume uptrend+
crossing = -50% share value! Didnot see it coming. Why? jdm
Drug fails trump technical analysis every time.
Technical analysis is in the eye of the beholder. How could such a promising chart be so empty of predictive value?...jdm
The old saying is
works until it doesn't.
Add a reply...
Latest StockTalks »
people get GERN breaking news and analysis by email alert.
Get email alerts on GERN »
Get latest price
From other sites
Geron (GERN) Q1 Loss In-Line, Imetelstat Remains in Focus
at Zacks.com (May 6, 2016)
Geron (GERN) Q1 Earnings: What's in Store for the Stock?
at Zacks.com (May 3, 2016)
The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics
at Zacks.com (Mar 29, 2016)
Geron Q4 Loss In-Line with Estimates, Imetelstat in Focus
at Zacks.com (Feb 26, 2016)
Geron (GERN) to Report Q4 Earnings: What's in Store?
at Zacks.com (Feb 23, 2016)